CD146 Paired‑Antibody Research Tools: Exploring Molecular Regulators of Adipose‑Tissue Metabolic Homeostasis

Research Background: CD146 from Tumour‑Associated Marker to Metabolic Research Target

CD146, also designated MCAM, belongs to the cell‑adhesion‑molecule protein family first identified within melanoma‑derived experimental samples. Early research projects focused largely on its roles within tumour progression, embryonic development and immune‑response biological processes. Contemporary laboratory studies expand its functional scope toward adipose‑tissue biology and metabolic‑homeostasis research.

Investigation groups have documented restricted CD146 expression patterns across adult mouse tissue specimens. Transcript and protein signals remain low across most adult organs, while distinct enrichment takes place within adipose tissue compartments. This tissue‑biased expression profile inspired further experimental work exploring CD146 functions within adipocyte biology and energy‑balance regulatory networks.

Multiple pre‑clinical mouse models support follow‑up mechanistic exploration. Experimental systems include high‑fat‑diet‑driven obesity models, age‑related obesity models, and db/db mice carrying leptin‑receptor genetic deficiency. These in‑vivo platforms provide reproducible frameworks to dissect CD146‑dependent molecular events within metabolic research projects.

Expression Profiling and Phenotypic Observations from CD146 Genetic‑Manipulation Studies

Research datasets demonstrate significant CD146 up‑regulation within adipose tissues collected from obese mouse experimental groups. Parallel analysis of human biospecimen materials shows positive correlation between CD146 abundance and body‑mass‑index metrics within sample cohorts. Observed expression elevation mainly localises to adipocyte cell populations inside fat depots.

Global CD146 knockout and adipocyte‑specific conditional knockout mouse lines enable loss‑of‑function phenotype characterisation. Both genetic‑modification strategies can mitigate high‑fat‑diet‑triggered experimental outcomes including fat mass expansion, hepatic lipid accumulation and insulin‑response impairment.

CD146‑deficient experimental animals display reduced body weight and adipose tissue mass under matched feeding conditions. These knockout groups also exhibit improved glucose tolerance, enhanced insulin sensitivity and elevated whole‑body energy‑expenditure readouts relative to wild‑type control littermates. Such phenotypic observations establish CD146 as a functional mediator of adipose‑tissue dysfunction in laboratory obesity models.

Distinct CD146‑Mediated Signalling Outputs in Diverse Adipocyte Subpopulations

CD146 delivers divergent biological outputs depending on cell types and engaged ligand molecules within experimental systems. In pre‑adipocyte populations, CD146 acts as the cell‑surface receptor for adipokine ANGPTL2 secreted ligand molecules. Ligand‑receptor binding activates downstream CREB‑driven transcriptional cascades.

Activated CREB signalling further up‑regulates core adipogenic transcription factors C/EBPα and PPARγ, which collectively drive white‑adipocyte differentiation programmes. In mature white adipocytes, ANGPTL2‑CD146 signal axes stimulate secretion of pro‑inflammatory mediators TNF‑α, IL‑6 and IL‑1β. This signalling branch promotes lipogenic activity while repressing fatty‑acid‑oxidation biological processes.

Brown adipocyte experimental systems display another layer of mechanistic complexity. ANGPTL2 ligation to CD146 does not interfere with brown‑fat thermogenic capacity under assay conditions. When Galectin‑1 serves as binding partner, CD146 signalling suppresses UCP1 protein expression and thereby reduces therm‑related energy dissipation.

Additional regulatory circuits exist within macrophage cell populations. CD146 can physically interact with Gp130 protein complexes and modulate intracellular JNK‑STAT3 signalling balances. This molecular crosstalk shapes pro‑inflammatory macrophage polarisation profiles and extends CD146 regulatory influence over obesity‑linked low‑grade inflammatory responses.

Research Insights from CD146‑Blocking Antibody AA98 in Pre‑Clinical Model Systems

Antibody‑mediated ligand‑blocking approaches represent one common strategy for target‑validation laboratory work. The AA98 monoclonal antibody can interrupt molecular interactions between CD146 and its partner ligands in cell‑based and animal‑model experiments. Assays using db/db mouse specimens document multiple measurable phenotypic shifts after AA98 intervention.

Experimental readouts include restrained adipose expansion, reduced chronic inflammatory signals, and decreased serum concentrations for cholesterol, triglycerides and free fatty‑acid molecules. Treated groups show restored glucose tolerance and improved insulin‑response performance, alongside enhanced brown‑adipocyte‑dependent energy expenditure.

Low endogenous CD146 abundance within heart, brain, kidney, liver and skeletal‑muscle tissue samples may limit potential off‑target effects in laboratory animal setups. Such observations reinforce the value of high‑specificity detection antibodies for reliable CD146 expression profiling across diverse sample types in metabolic research workflows.

Reagent Support from ANT BIO PTE. LTD. for CD146‑Centered Adipose‑Biology Research

ANT BIO PTE. LTD. provides rat‑derived anti‑mouse CD146 antibody clone S‑R606 for basic molecular and tissue‑oriented laboratory assays. This reagent has undergone target‑specificity assessment and batch‑consistency quality‑control procedures during production workflows.

Validated application scenarios cover flow cytometry, immunohistochemistry and Western blot analytical platforms. Researchers can deploy these antibody products to quantify CD146 protein abundance, characterise cell‑surface marker profiles, and support mechanistic investigations of adipocyte differentiation and obesity‑associated signalling networks.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high‑quality, reliable reagents and comprehensive solutions. Our specialized sub‑brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer‑centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.

Disclaimer
This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.